Progress in Nanomedicine: Approved and Investigational Nanodrugs.

: Nanomedicine is a relatively new and rapidly evolving field combining nanotechnology with the biomedical and pharmaceutical sciences.1-3 Nanoparticles (NPs) can impart many pharmacokinetic, efficacy, safety, and targeting benefits when they are included in drug formulations.1-5 Many nanodrugs have entered clinical practice, and even more are being investigated in clinical trials for a wide variety of indications.2 However, nanopharmaceuticals also face challenges, such as the need for better characterization, possible toxicity issues, a lack of specific regulatory guidelines, cost-benefit considerations, and waning enthusiasm among some health care professionals. 4,5 For these reasons, expectations regarding nanodrugs that are in early stages of development or clinical trials need to remain realistic.4.

[1]  R. Advani,et al.  A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study , 2013, Leukemia & lymphoma.

[2]  H. Sharma,et al.  Nanoparticles aggravate heat stress induced cognitive deficits, blood-brain barrier disruption, edema formation and brain pathology. , 2007, Progress in brain research.

[3]  Mauro Ferrari,et al.  Safety of Nanoparticles in Medicine. , 2015, Current drug targets.

[4]  R. Mariani-Costantini,et al.  Immunotoxicity of nanoparticles. , 2011, International journal of immunopathology and pharmacology.

[5]  C. Goss,et al.  Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection , 2013, Thorax.

[6]  Patrick Soon-Shiong,et al.  Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Fang Wang,et al.  Application of Drug Nanocrystal Technologies on Oral Drug Delivery of Poorly Soluble Drugs , 2012, Pharmaceutical Research.

[8]  Tracy K. Pettinger,et al.  Nanopharmaceuticals (part 1): products on the market , 2014, International journal of nanomedicine.

[9]  H. Havel.  Where Are the Nanodrugs? An Industry Perspective on Development of Drug Products Containing Nanomaterials , 2016, The AAPS Journal.

[10]  S. Schwartz,et al.  A Single-blind, Placebo-controlled, Dose-ranging Trial of Oral Hepatic-directed Vesicle Insulin Add-on to Oral Antidiabetic Treatment in Patients With Type 2 Diabetes Mellitus , 2014, Journal of diabetes science and technology.

[11]  Kristofer J. Thurecht,et al.  Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.

[12]  C. L. Ventola.  The nanomedicine revolution: part 3: regulatory and safety challenges. , 2012, P & T : a peer-reviewed journal for formulary management.

[13]  Y. Liu,et al.  Understanding the toxicity of carbon nanotubes. , 2013, Accounts of chemical research.

[14]  Joelle M. Brown,et al.  A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days , 2011, PloS one.

[15]  M. Radomski,et al.  The Nanopharmacology and Nanotoxicology of Nanomaterials: New Opportunities and Challenges. , 2016, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[16]  Xiaoying Zhang,et al.  Gold Nanoparticles: Recent Advances in the Biomedical Applications , 2015, Cell Biochemistry and Biophysics.

[17]  Xiu Shen,et al.  Size-dependent in vivo toxicity of PEG-coated gold nanoparticles , 2011, International journal of nanomedicine.

[18]  A. Domb,et al.  Antimicrobial evaluation of quaternary ammonium polyethyleneimine nanoparticles against clinical isolates of pathogenic bacteria. , 2015, IET nanobiotechnology.

[19]  D. Balding,et al.  HLA Sequence Polymorphism and the Origin of Humans , 2006 .

[20]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[21]  David M. Brown,et al.  The Role of Free Radicals in the Toxic and Inflammatory Effects of Four Different Ultrafine Particle Types , 2003, Inhalation toxicology.

[22]  Henri Szwarc,et al.  Toxicity studies of carbon nanotubes. , 2007, Advances in experimental medicine and biology.

[23]  David M. Brown,et al.  Ultrafine Particle-Mediated Activation of Macrophages: Intracellular Calcium Signaling and Oxidative Stress , 2000, Inhalation toxicology.

[24]  E. Cho,et al.  A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer , 2014, Cancer Chemotherapy and Pharmacology.

[25]  Lawrence Tamarkin,et al.  Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine , 2010, Clinical Cancer Research.

[26]  H. Kantarjian,et al.  Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML , 2015, Cancer.

[27]  T. Spelman,et al.  SPL7013 Gel (VivaGel®) Retains Potent HIV-1 and HSV-2 Inhibitory Activity following Vaginal Administration in Humans , 2011, PloS one.

[28]  A. Secord,et al.  A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. , 2008, Gynecologic oncology.

[29]  I. Nestorov,et al.  A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology , 2012, Journal of clinical pharmacology.

[30]  V. Weissig,et al.  Nanopharmaceuticals (part 2): products in the pipeline , 2015, International journal of nanomedicine.

[31]  R. Kumria,et al.  Nanocrystals: Current Strategies and Trends , 2012 .